Acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine) are approved by the U.S. Food and Drug Administration for the treatment of AD patients (Unzeta et al., 2016; Kaushik et al., 2018; Alzheimer's Association, 2020). This evidence concerns the gene ACHE and Alzheimer disease.